4.75
-0.17(-3.46%)
Currency In USD
Previous Close | 4.92 |
Open | 5.17 |
Day High | 5.17 |
Day Low | 4.72 |
52-Week High | 14.6 |
52-Week Low | 3.79 |
Volume | 1.05M |
Average Volume | 997,900 |
Market Cap | 237.99M |
PE | -3.57 |
EPS | -1.33 |
Moving Average 50 Days | 5.18 |
Moving Average 200 Days | 6.49 |
Change | -0.17 |
If you invested $1000 in Candel Therapeutics, Inc. (CADL) since IPO date, it would be worth $687.86 as of June 20, 2025 at a share price of $4.815. Whereas If you bought $1000 worth of Candel Therapeutics, Inc. (CADL) shares 3 years ago, it would be worth $1,428.78 as of June 20, 2025 at a share price of $4.815.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
GlobeNewswire Inc.
Jun 06, 2025 12:05 PM GMT
Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial developmentNEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeuti
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
GlobeNewswire Inc.
May 28, 2025 12:05 PM GMT
NEEDHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer,
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
GlobeNewswire Inc.
May 27, 2025 12:05 PM GMT
NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer,